English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
News
The 2022 iCMLf Prize is awarded to Giora Sharf and Jan Geissler
March 2022 - This year, the iCMLf Directors and Advisors have selected two powerful voices for patients with CML as recipients for the iCMLf Prize. Giora Sharf (Israel) and Jan Geissler (Germany) have used the experience of their own diagnosis to help other patients. They have tirelessly advocated for the needs of patients with CML across the world over the past decades. The iCMLf Prize recognizes outstanding contributions to the improvement of CML treatment in low- and middle-income countries. As giants in patient advocacy around the world, Jan and Giora are worthy recipients of this award.
The 2022 Goldman Prize is awarded to Professor Andreas Hochhaus
March 2022 - We are delighted to announce Professor Andreas Hochhaus, Head of the Department of Hematology and Medical Oncology at Jena University Hospital as the 2022 Goldman Prize recipient. He receives the prize in recognition of his outstanding clinical leadership in CML and for his lifelong contributions to the optimization of CML therapy – through his work on mechanisms of resistance and stem cell persistence, through leading clinical studies and through the development of clinical recommendations. The annual Goldman Prize awarded in honour of Professor John Goldman, acknowledges outstanding lifetime contributions to the management of patients with CML.
The 2022 Rowley Prize is awarded to Professor Oliver Hantschel
March 2022 - The iCMLf awards the 2022 Rowley Prize to Professor Oliver Hantschel, for his scientific research on structural biochemistry of tyrosine kinase oncoproteins that helped to describe novel targetable pathways in the pathophysiology of BCR-ABL. The Rowley Prize is awarded to celebrate people who have made outstanding lifetime contributions to the understanding of the biology of CML.
February 28th is Rare Disease Day. We show our colours for people with CML.
February 2022 - Along with many other organisations, today we show our colours and support Rare Disease Day 2022.
There are over 300 million people living with a rare disease worldwide –
A global rare disease community with a powerful voice together.
Our voice goes especially for people living with CML around the world. With an incidence of between 1 and 2 people per 100,000 people annually, CML is a rare disease. But with the increasing prevalence of CML, a concerted global effort working towards a cure is imperative.
The iCMLf TFR Alliance - Optimising Treatment Free Remission
While a cure for CML remains the ultimate goal, treatment free remission (TFR) is often the treatment target for those on TKI therapy. Still, with around 50-60% of people achieving sustained TFR there is much room for improvement.
The iCMLf TFR Alliance has now evolved into a global network of 41 collaborators from 21 countries aiming to enhance successful TFR attempts for people with CML.
In 2021 the TFR Alliance began the process to establish an International TFR Registry that will be an optimal way to study clinically (and pharmaco-economically) important research questions on treatment-free remission.
To set up the registry, initial seed funding from the iCMLf was awarded to the Swedish CML Registry Group following a call for proposals. In August, a first meeting was held to define priorities for the TFR Registry and a survey to define the registry parameters and outcomes was sent out to the community. We meet in February to finalise the registry priorities and move into set up phase.
Learn more about the TFR Registry and how to get involved...
Recognising outstanding contributions to CML. Nominate now for the 2022 iCMLf Prizes
January 2022 - Great progress has been made in CML over the past decades, but scientists and clinicians around the world continue to work hard to develop new therapies and treatment strategies for patients globally with the ultimate aim to find a cure for CML.
We continue with our tradition to recognise individuals who have played a major role in advancing our understanding of the biology of CML and to improving the management of CML. Ultimately, it’s personal commitment, passion and tireless work that drives research and makes a difference for people with CML.
Since the first iCMLf Rowley Prize was awarded to Professor Brian Druker in 2009, we have honoured 29 scientists and clinicians with the three specific iCMLf Prizes.
Who would you like to see awarded the iCMLf prizes this year?
